- The Coulter Foundation’s Wallace H.
Coulter Award for Healthcare Innovation Recognizes Excellence and
Leadership in Clinical Diagnostic Medicine -
Veracyte, Inc. (NASDAQ: VCYT) announced today that the company’s
Chairman and CEO Bonnie Anderson is the recipient of the 2017
Wallace H. Coulter Award for Healthcare Innovation. Dr. Lori
Setton, president of the Biomedical Engineering Society BMES, will
present the award to Ms. Anderson today at the 2017 BMES Annual
Meeting in Phoenix, AZ. Ms. Anderson will deliver a keynote lecture
during a plenary session at the meeting.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171013005391/en/
Bonnie Anderson, Chairman and CEO,
Veracyte, Inc. (Photo: Business Wire)
The Coulter Award for Healthcare Innovation recognizes
excellence and leadership in clinical diagnostic medicine, and
honors the lifelong achievements of Mr. Coulter, co-founder of the
company that later became Beckman Coulter. A committee comprising
representatives from the Coulter Foundation and BMES determine
nominations and select an annual winner. Ms. Anderson follows
Medtronic Chairman and CEO Omar Ishrak, who received the award in
2016.
“This award was created to recognize innovation in medical
research and engineering that improves healthcare,” said Kevin
Otto, co-chair of the BMES Annual Meeting. “Bonnie Anderson and
Veracyte embody this innovative spirit, as well as the leadership
and expertise that are necessary to translate innovative ideas into
real-world tools that have a meaningful impact on patient
outcomes.”
Ms. Anderson founded Veracyte in 2008 and took the company
public in 2013. With a business plan and $21 million dollars in
venture capital funding, Ms. Anderson and her world class team
created a pioneering genomic diagnostics company that is setting
new standards in disease diagnosis. In less than 10 years, Veracyte
has introduced three first-to-market commercial products that have
helped tens of thousands of patients avoid unnecessary surgery and
are providing hundreds of millions of dollars in savings to the
health care system.
“I am so honored to receive this award, because it recognizes
exactly what we have worked so hard to do at Veracyte - develop
innovative diagnostic products that have a real impact on
patients,” Ms. Anderson said. “I am also incredibly humbled because
my 18-year career at Beckman Coulter, where I was offered amazing
opportunities to learn and lead, is much of the reason I’m here
today. The company and Mr. Coulter ignited an entrepreneurial
passion, which ultimately inspired us to create Veracyte.”
Ms. Anderson’s corporate and industry leadership have been
recognized consistently over the past several years. Fast Company
named her to its list of “100 Most Creative People in Business
2015” and the San Francisco Business Times has selected her as one
of the “Bay Area’s Most Admired CEOs.”
About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company
that is providing trustworthy and actionable answers that
fundamentally improve patient care when current diagnostic tests
are uncertain. The company’s products uniquely combine genomic
technology, clinical science and machine learning to provide
answers that give physicians and patients a clear path forward
without risky, costly surgery that is often unnecessary. Since its
founding in 2008, Veracyte has commercialized three genomic tests,
which are transforming the diagnosis of thyroid cancer, lung cancer
and idiopathic pulmonary fibrosis and collectively target a $2
billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the
Afirma logo are trademarks of Veracyte, Inc.
About the Wallace H. Coulter Foundation
Wallace H. Coulter, the benefactor of the
Coulter Foundation, invented the Coulter Principal, an
electronic method of counting and classifying microscopic particles
suspended in fluid. Coulter utilized this principal to create an
apparatus known as the “Coulter Counter” that revolutionized the
practice of clinical laboratory medicine by counting and
classifying blood cells, a process that was previously done
manually. Throughout his lifetime, Coulter was a champion of
practical translational research directed to improving the scope
and quality of clinical diagnostic medicine. As a continuation of
Mr. Coulter’s life-long work, the Coulter Foundation supports the
discipline of biomedical engineering at universities and medical
schools. The Foundation provides risk capital, expertise, and
guidance to help innovative initiatives realize their potential,
and is guided by the principle to address the needs of the
under-served, under-resourced, and/or under-represented.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that
we are setting new standards in disease diagnosis and the potential
benefits of the company’s tests. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Forward-looking statements involve risks
and uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: demand for our tests, the
applicability of clinical results to actual outcomes; laws and
regulations applicable to our business, including potential
regulation by the Food and Drug Administration or other
regulatory bodies; our ability to successfully achieve and
maintain adoption of and reimbursement for our products; the amount
by which use of our products are able to reduce invasive procedures
and misdiagnosis, and reduce healthcare costs; the occurrence and
outcomes of clinical studies; the timing and publication of
clinical study results; and other risks set forth in the company's
filings with the Securities and Exchange Commission, including
the risks set forth in the company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 2017. These forward-looking
statements speak only as of the date hereof
and Veracyte specifically disclaims any obligation to
update these forward-looking statements.
Veracyte, Percepta, and the Veracyte logo are trademarks of
Veracyte, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171013005391/en/
Veracyte, Inc.Media:Tracy Morris,
650-380-4413Tracy.Morris@Veracyte.comorInvestors:Jackie
Cossmon, 650-243-6371jackie@veracyte.com
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024